Literature DB >> 3048108

Pseudophakic bullous keratopathy.

E J Cohen1, S E Brady, K Leavitt, M Lugo, M G Speaker, P R Laibson, J J Arentsen.   

Abstract

We reviewed the records of all patients with pseudophakic bullous keratopathy (271 eyes, 251 patients) seen during a six-month period to determine predisposing factors, associated problems, current management, and visual outcome. Pseudophakic bullous keratopathy was associated most frequently with anterior chamber intraocular lenses in general (155 of 271), and with Leiske style lenses in particular (100 of 271). It was associated with a visual acuity of 20/200 or less in 206 eyes and a visual acuity of counting fingers or less in 129 of the eyes at the initial examination. Penetrating keratoplasties had been performed in 189 of the eyes. After penetrating keratoplasty, 108 of 189 of the eyes had a visual acuity of 20/200 or less (mean follow-up, 15 months). Visual acuity improved with longer follow-up, and among patients with a minimum follow-up of two years, 23 of 36 eyes had a visual acuity of 20/100 or better. Most grafts were clear (145 of 189). Pseudophakic bullous keratopathy was associated with marked visual loss, which was permanent despite clear grafts in 29 of 92 eyes followed-up for one year or longer.

Entities:  

Mesh:

Year:  1988        PMID: 3048108     DOI: 10.1016/0002-9394(88)90359-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Effects of posterior chamber lens implantation on the endothelium of transplanted corneas.

Authors:  N Ohguro; M Matsuda; S Kinoshita
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

2.  Penetrating keratoplasty for pseudophakic corneal oedema.

Authors:  J Kwartz; B Leatherbarrow; P Dyer; A E Ridgway; A B Tullo
Journal:  Br J Ophthalmol       Date:  1995-05       Impact factor: 4.638

3.  An analysis of corneal endothelial and graft survival in pseudophakic bullous keratopathy.

Authors:  A Sugar
Journal:  Trans Am Ophthalmol Soc       Date:  1989
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.